Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters.
We examined whether reductions in body fat stores and insulin resistance in Syrian hamsters induced by bromocriptine are associated with reductions in daily norepinephrine (NE) and serotonin activities as indicated by their extracellular metabolite levels in the ventromedial hypothalamus (VMH). High levels of these monoamines within the VMH have been suspected to induce obesity and insulin resistance. Microdialysate samples from the VMH of freely moving obese male hamsters (BW: 208 +/- 5 g) were collected hourly over a 25-hour period before bromocriptine treatment, during the first day of and after 2 weeks of bromocriptine treatment (800 microg/animal daily, i.p.), and body composition and glucose tolerance analyses were conducted before and after 2 weeks of treatments. The microdialysate samples were analyzed by HPLC for metabolites of serotonin: 5-hydroxy-indoleacetic acid (5-HIAA), NE: 3-methoxy-4-hydroxy-phenylglycol (MHPG), and dopamine: homovanillic acid (HVA). Bromocriptine treatment for 14 days significantly reduced body fat by 60% and areas under the glucose and insulin curves during a glucose tolerance test by 50 and 46%, respectively. Concurrently, extracellular VMH contents of 5-HIAA, MHPG, and HVA were reduced by 50, 29 and 66%, respectively (p < 0.05). Similarly, VMH 5-HIAA and MHPG contents were 48 and 44% less, respectively (p < 0.05), in naturally glucose-tolerant hamsters compared with naturally glucose-intolerant hamsters. Bromocriptine induced reductions of body fat, and improvements in glucose intolerance may result in part from its ability to decrease serotonin and NE activities in the VMH.
Luo
S
S
Ergo Science Corporation, Charlestown, Mass 02129, USA. SLUO@ERGO.COM
Meier
A H
AH
Cincotta
A H
AH
D000273:Adipose Tissue; D000818:Animals; D015306:Biogenic Monoamines / Q000378:metabolism*; D001823:Body Composition / Q000187:drug effects*; D001971:Bromocriptine / Q000494:pharmacology*; D002851:Chromatography, High Pressure Liquid; D002940:Circadian Rhythm; D006224:Cricetinae; D004298:Dopamine / Q000378:metabolism; D018149:Glucose Intolerance; D006719:Homovanillic Acid / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D007033:Hypothalamus, Middle / Q000378:metabolism*; D007333:Insulin Resistance; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000378:metabolism; D017551:Microdialysis; D009765:Obesity; D012701:Serotonin / Q000378:metabolism
D015306:Biogenic Monoamines; D012701:Serotonin; D001971:Bromocriptine; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D004298:Dopamine; D006719:Homovanillic Acid